The estimated Net Worth of Joseph E Payne is at least $32.2 Milione dollars as of 23 November 2022. Mr. Payne owns over 5,000 units of Arcturus Therapeutics Inc stock worth over $31,052,435 and over the last 6 years he sold ARCT stock worth over $0. In addition, he makes $1,165,820 as President, Chief Executive Officer e Director at Arcturus Therapeutics Inc.
Joseph has made over 3 trades of the Arcturus Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ARCT stock worth $82,550 on 23 November 2022.
The largest trade he's ever made was buying 5,000 units of Arcturus Therapeutics Inc stock on 23 November 2022 worth over $82,550. On average, Joseph trades about 1,222 units every 131 days since 2019. As of 23 November 2022 he still owns at least 1,480,097 units of Arcturus Therapeutics Inc stock.
You can see the complete history of Mr. Payne stock trades at the bottom of the page.
Joseph E. Payne serves as President, Chief Executive Officer, Director of the Company. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Mr. Payne’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko Corporation as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor’s Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management. Mr. Payne is nominated for re-election on our Board because of his position as our President and Chief Executive Officer and his significant experience in the pharmaceutical sector. As a member of our executive team, Mr. Payne serves a vital function in the link between management and our Board, enabling the Board to perform its oversight function with the benefits of management’s perspective on the business.
As the President, Chief Executive Officer e Director of Arcturus Therapeutics Inc, the total compensation of Joseph Payne at Arcturus Therapeutics Inc is $1,165,820. There are 1 executives at Arcturus Therapeutics Inc getting paid more, with Andrew Sassine having the highest compensation of $1,326,880.
Joseph Payne is 48, he's been the President, Chief Executive Officer e Director of Arcturus Therapeutics Inc since 2013. There are 9 older and 3 younger executives at Arcturus Therapeutics Inc. The oldest executive at Arcturus Therapeutics Holdings Inc is Edward Holmes, 79, who is the Independent Director.
Joseph's mailing address filed with the SEC is C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO, CA, 92121.
Over the last 12 years, insiders at Arcturus Therapeutics Inc have traded over $137,035,874 worth of Arcturus Therapeutics Inc stock and bought 56,234 units worth $767,374 . The most active insiders traders include William M Kahane, Nicholas S Schorsch e Peter C Farrell. On average, Arcturus Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $1,034,818. The most recent stock trade was executed by Jing L. Marantz on 14 June 2024, trading 3,131 units of ARCT stock currently worth $65,688.
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
Arcturus Therapeutics Inc executives and other stock owners filed with the SEC include: